Paris, France, June 5, 2025 – The European Microbiome Innovation for Health (EMIH) announced a significant expansion, welcoming 13 new members, including private companies, public organizations, and a European patient advocacy group to its coalition. This growth reinforces EMIH’s mission to drive microbiome-based medical innovation and position Europe as a global leader in this rapidly evolving field.
“This expansion reflects the growing influence of EMIH and the current momentum of microbiome innovation in Europe. We look forward to working alongside these leading organizations as we seek to implement tangible policy solutions that accelerate the development and integration of microbiome-based therapeutic innovations.”
Stated Hervé Affagard, President of EMIH and CEO of MaaT Pharma.
The 13 new members joining EMIH include (in alphabetical order):
- BioGaia, an innovative Swedish healthcare company, develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via its own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com
- Cancer Patients Europe is a pan-European cancer patient association uniting cancer patients, carers, and survivors, that envisions reducing the burden of cancer on patients and survivors, their carers, the health care systems, and society as a whole across Europe through research, advocacy and policy work. As of April 2025, CPE has 66 members in 27 countries. cancerpatientseurope.org
- EnteroBiotix is a clinical-stage biotechnology company developing therapeutics to treat gastrointestinal and hepatic diseases. EnteroBiotix’s therapies contain highly diverse ecosystems of microorganisms stabilized using proprietary platform technology and designed to improve gut health by augmenting the gut microbiome. www.enterobiotix.com
- Institut Mérieux, an independent family group, is contributing its experience in biology to improve medicine and public health across the globe to fight against infectious diseases and cancer. Institut Mérieux employs 23,000 people around the world and is present in 45 countries, with 4.38 billion euros in sales. www.institut-merieux.com
- The International Probiotics Association – Europe (IPA Europe) is the European chapter of the International Probiotics Association (IPA) bringing together the probiotic sector’s stakeholders including but not limited to academia, scientists, health care professionals, consumers, industry, and regulators. The mission of IPA is to advance the safe and effective use of probiotics across Europe and worldwide. IPA & IPA Europe are engaged in establishing a clear framework for the use of the term probiotics, to better address the challenges the probiotic sector is facing and contribute actively to the European and international debate.Holding NGO status before Codex Alimentarius, the IPA is also recognized as the Global Voice of Probiotics®. ipaeurope.org – internationalprobiotics.org
- IPA Europe is a non-profit international association, based in the heart of the European district in Brussels, that represents the interests of the European Probiotic Industry in all discussions with the European Institutions, the European Food and Safety Authority (EFSA), international institutions and national authorities, aiming to consolidate the probiotic category and boost EU competitiveness. www.ipaeurope.org
- Life Avocats is a law firm which assists organisations involved in digital health and life sciences with all the regulatory issues relating to the life cycle of their products and solutions: development, pre-clinical and clinical research, market access, distribution, health inspections. www.life-avocats.com
- Mbiomics develops microbiome-based therapeutics to transform the treatment of severe and chronic diseases. Combining proprietary precision analytics with patient insights, it creates targeted microbial communities for specific indications while addressing patient variability. mbiomics.com
- Microviable is a biotech company at preclinical stage developing novel biological drugs based on living bacteria, for infectious diseases and oncology. The company’s assets are orally delivered capsules containing living bacteria from the gut microbiome. www.microviable.com
- Microbiotica is a private, clinic-ready, biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programmes in immuno-oncology and inflammatory bowel disease. microbiotica.com
- MRM Health is a clinical-stage biotech developing innovative therapies for inflammatory, CNS, and metabolic diseases. Its lead program, MH002, is advancing toward pivotal clinical development for Ulcerative Colitis and the orphan disease Pouchitis. mrmhealth.com
- Nextep is a consulting firm specializing in strategic healthcare issues and transformation of healthcare practices. The firm is convinced that sustainable, virtuous transformation of the healthcare system requires a global, systemic approach. nextep-health.com
- PiLeJe has been working to enable everyone to achieve lasting health since 1991. Convinced that a healthcare approach focused on well-being is possible, PiLeJe promotes health and well-being for all in a personalized way, at every stage of life. This is the goal of the health solutions developed and recommended by healthcare professionals. www.pileje.com
- SwipeBiome, a French tech-bio leader, transforming microbiome care by delivering real‑time, non‑invasive biotic prescriptions through advanced AI and integrated data insights. By decoding biotic interactions within the biome, it transforms complex data into personalized, actionable insights. swipebiome.com
These organizations join EMIH’s valued founding members, including Bioaster, Biocodex, Biofortis, Biose Industrie, GMT Science, INRAe, Lallemand Health Solutions, Enosis Santé, Pelican Health, MaaT Pharma, Microbiome Foundation, Nexbiome, Novobiome, and Seventure Partners.
EMIH is dedicated to solidifying and advancing Europe’s industrial microbiome sector, with the goal of fostering medical innovation and securing a prominent global position for European stakeholders. EMIH’s mission is to ensure that all patients across Europe have equitable access to high-quality, microbiota-based therapies, diagnostics, and bioproduction. By uniting key industry players and promoting innovation through a robust yet balanced regulatory framework, EMIH aims to foster a thriving ecosystem that advances microbiota science to address unmet medical needs, improve patient outcomes, and position Europe as a global leader in this field. EMIH and its members are dedicated to advancing knowledge and fostering the development of bioproductions, diagnostics, and medical devices based on the microbiome for human health. The organization is committed to ensuring equitable access to these innovations by adhering to regulatory frameworks that uphold the highest quality standards, while maintaining an economic balance to support ongoing therapeutic innovation.
In 2024, EMIH and the US-based Microbiome Therapeutics Innovation Group (MTIG) entered a strategic collaboration to advance microbiome drug development, explore synergies between international regulators, and convene cross-continental meetings to incorporate the perspectives of a wide-range of drug developers.
All pharmaceutical and biotechnology companies seeking regulatory approvals in Europe for microbiome bioproductions, diagnostics, and medical devices are eligible for membership consideration in EMIH. If you are interested in learning more, please contact EMIH here.
About European Microbiome Innovation for Health
EMIH is an independent coalition within the European Union, the United Kingdom, and Switzerland, currently comprising 27 major players from the public and private sectors. From the laboratory to the patient’s bedside, EMIH covers the entire value chain of the microbiome industry. Its goal is to position Europe as a global leader in the development, production, and commercialization of microbiome-based therapeutic innovations.
EMIH members include Bioaster, Biocodex, BioGaia, Biofortis, Biose Industrie, Cancer Patients Europe, Enosis Santé, EnteroBiotix, GMT Science, INRAe, Institut Mérieux, IPA Europe, Lallemand Health Solutions, Life Avocats, MaaT Pharma, mbiomics, Microbiotica, Microbiome Foundation, Microviable, MRM Health, Nexbiome, Nextep Health, Novobiome, Pelican Health, PiLeJe, Seventure Partners and SwipeBiome. For more information, please visit www.europeanmicrobiome.org
European Microbiome Innovation for Health Contacts
Memberships: Office@europeanmicrobiome.org
Media Relations: p.richaud@europeanmicrobiome.org
